Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Translocation of the MLL Gene at 11q23 or Advanced Hematologic Malignancies
Conditions
Interventions
EPZ-5676
Locations
8
United States
Mayo Clinic Scottsdale-Phoenix
Scottsdale, Arizona, United States
Northwestern University
Chicago, Illinois, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Duke University Health System
Durham, North Carolina, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
UT MD Anderson Cancer
Houston, Texas, United States
Start Date
September 1, 2012
Primary Completion Date
November 1, 2015
Completion Date
February 1, 2016
Last Updated
March 26, 2024
NCT05564390
NCT06303193
NCT06847867
NCT07320235
NCT05969860
NCT06782542
Lead Sponsor
Epizyme, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions